Personalis (NASDAQ:PSNL) Releases Earnings Results, Beats Estimates By $0.05 EPS

Personalis (NASDAQ:PSNL) announced its quarterly earnings data on Thursday. The company reported ($0.26) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.05, FiscalAI reports. The firm had revenue of $17.35 million for the quarter, compared to analyst estimates of $17.12 million. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.

Here are the key takeaways from Personalis’ conference call:

• Personalis reported explosive clinical growth—6,183 tests in Q4 (329% YoY) and >16,000 tests in 2025—and announced Medicare coverage for breast and lung surveillance while guiding to 43,000–45,000 tests in 2026 and $78–80M in revenue.
• Biopharma MRD revenue is accelerating (≈240% YoY growth in 2025) as the company shifts from lower‑value legacy projects to higher‑value, multi‑year MRD partnerships, with MRD/pharma revenue guided to $20–21M in 2026.
• Margins and profitability will be pressured near term—gross margin compressed to 11% in Q4 and 22.7% for 2025, 2026 gross margin guide is 15–20%, and management expects a ~<$105M net loss and ~$100M cash burn in 2026 despite a $240M cash balance.
• Product innovation continued with the launch of the opt‑in Real‑Time Variant Tracker, now in an early access program, designed to detect therapy‑targetable and resistance mutations during MRD surveillance and potentially increase clinical utility and physician stickiness.

Personalis Stock Performance

PSNL stock traded up $0.72 on Thursday, reaching $9.03. The company’s stock had a trading volume of 1,492,475 shares, compared to its average volume of 1,115,608. The business has a fifty day simple moving average of $8.82 and a two-hundred day simple moving average of $7.93. The firm has a market cap of $801.86 million, a PE ratio of -10.26 and a beta of 1.98. Personalis has a 12-month low of $2.83 and a 12-month high of $11.50.

Analyst Ratings Changes

Several research analysts have commented on PSNL shares. HC Wainwright lifted their price target on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Personalis in a research report on Thursday, January 22nd. Guggenheim lifted their price objective on Personalis from $12.00 to $13.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Morgan Stanley increased their target price on Personalis from $9.00 to $11.00 and gave the company an “equal weight” rating in a report on Monday, December 1st. Finally, Lake Street Capital restated a “buy” rating and set a $11.00 price target on shares of Personalis in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Personalis has a consensus rating of “Moderate Buy” and a consensus price target of $10.86.

Hedge Funds Weigh In On Personalis

Several hedge funds and other institutional investors have recently modified their holdings of PSNL. Squarepoint Ops LLC bought a new position in Personalis during the 3rd quarter valued at about $123,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Personalis in the second quarter worth $123,000. Guggenheim Capital LLC bought a new stake in Personalis during the fourth quarter valued at about $108,000. New York State Common Retirement Fund bought a new position in Personalis in the 2nd quarter worth approximately $104,000. Finally, Brevan Howard Capital Management LP purchased a new position in Personalis during the third quarter valued at $97,000. Hedge funds and other institutional investors own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.